AbbVie Secures $56M in Royalty Victory Over Revance in Botox Patent Dispute
CHICAGO – AbbVie has secured a significant legal victory in its ongoing battle over Botox-related patents. A jury has awarded the pharmaceutical company $56 million in royalties from Revance Therapeutics, affirming AbbVie’s claims of patent infringement. The case revolved around a contested patent for the use of a specific botulinum toxin formulation, which AbbVie argued Revance had violated with its own injectable therapy. This ruling underscores AbbVie’s commitment to protecting its intellectual property, particularly given the competitive landscape in the cosmetic and therapeutic market for neuromodulators. AbbVie has been a dominant player in the botulinum … Read more